Preventing Metabolic Liver Disease Through Muscle-Liver Crosstalk

Abstract

Metabolic liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH), represent a growing clinical challenge globally. Recent advances in the understanding of muscle-liver crosstalk have highlighted the pivotal role of skeletal muscle in liver metabolism and disease prevention. This review synthesizes current evidence on the bidirectional communication between muscle and liver, elucidates underlying mechanisms, and explores clinical strategies to leverage this axis for metabolic liver disease prevention. Key focus areas include myokine signaling, insulin sensitivity, and the impact of exercise and pharmacological interventions on muscle-liver dynamics. The review concludes with guideline-based recommendations and future directions in the integration of muscle-targeted therapies for liver disease prevention in clinical practice.

Introduction

Metabolic liver diseases are increasingly prevalent, with NAFLD affecting up to 25% of the global adult population. These disorders arise from complex interactions involving adipose tissue, skeletal muscle, and the liver, leading to hepatic steatosis, inflammation, and ultimately fibrosis. Traditional management has focused on hepatic pathology, but emerging evidence underscores the significance of muscle-liver crosstalk in metabolic regulation. Understanding this relationship is essential for developing multifaceted preventive and therapeutic strategies, particularly as sedentary lifestyles and obesity rates continue to rise, amplifying the burden of metabolic liver disease worldwide.

Epidemiology / Disease Burde

NAFLD is now considered the most common chronic liver disease, affecting up to 1.7 billion individuals globally. Its spectrum ranges from simple steatosis to NASH, cirrhosis, and hepatocellular carcinoma. The strong association with obesity, insulin resistance, and type 2 diabetes mellitus (T2DM) makes NAFLD a major contributor to morbidity and mortality. Sarcopenia, or loss of skeletal muscle mass and function, has emerged as an independent risk factor for both the development and progression of NAFLD, further highlighting the intricate connection between muscle health and liver pathology. Epidemiological data indicate that individuals with low muscle mass have a significantly higher risk of advanced liver disease, emphasizing the public health imperative to address muscle-liver interactions in prevention strategies.

Pathophysiology

The pathophysiology underlying muscle-liver crosstalk is multifactorial. Skeletal muscle plays a central role in systemic glucose and lipid metabolism. Through the secretion of myokines muscle-derived cytokines such as irisin, myostatin, and interleukin-6 muscle tissue communicates with the liver to modulate insulin sensitivity, inflammation, and hepatic lipid handling. In states of insulin resistance and sarcopenia, impaired myokine signaling and reduced glucose uptake in muscle contribute to increased lipolysis and free fatty acid (FFA) flux to the liver, exacerbating hepatic steatosis. Conversely, healthy muscle mass and function enhance hepatic insulin sensitivity, decrease hepatic fat accumulation, and mitigate inflammatory processes. Mitochondrial dysfunction, chronic inflammation, and altered autophagy in both tissues further perpetuate metabolic derangements, establishing a vicious cycle between muscle and liver.

Risk Factors

Risk factors for metabolic liver disease extend beyond traditional hepatic insults to encompass systemic metabolic disturbances. Key risk factors include obesity, sedentary behavior, T2DM, metabolic syndrome, and, importantly, sarcopenia. Age-related muscle loss, malnutrition, chronic illnesses, and physical inactivity contribute to diminished muscle mass and strength, enhancing susceptibility to NAFLD and NASH. Genetic predisposition, ethnicity, and underlying endocrine disorders such as hypothyroidism also modulate risk. The intersection of these factors underscores the necessity of holistic risk assessment in individuals at risk for metabolic liver disease.

Clinical Features

Metabolic liver disease is often clinically silent in early stages, with many patients identified incidentally via elevated liver enzymes or imaging. As disease progresses, symptoms such as fatigue, malaise, and right upper quadrant discomfort may emerge. In advanced stages, clinical features include jaundice, ascites, and signs of liver failure. Importantly, individuals with concurrent sarcopenia may present with muscle weakness, decreased physical performance, and increased frailty, which can confound the clinical picture and negatively impact prognosis. Recognition of these overlapping manifestations is vital for comprehensive clinical assessment.

Diagnosis

Diagnosis of metabolic liver disease incorporates a combination of clinical evaluation, biochemical markers, and imaging modalities. Elevated transaminases, hepatic steatosis on ultrasound or MRI, and exclusion of secondary liver diseases are core diagnostic criteria for NAFLD. Assessment of muscle mass and function using techniques such as bioelectrical impedance analysis, dual-energy X-ray absorptiometry (DEXA), and handgrip strength testing is increasingly recommended to identify sarcopenia. Liver biopsy remains the gold standard for staging, particularly in cases where NASH or advanced fibrosis is suspected. Emerging biomarkers, including circulating myokines and fibrosis scores, may enhance diagnostic precision and risk stratification in the future.

Treatment & Management

Current management of metabolic liver disease emphasizes lifestyle interventions, including dietary modification, weight loss, and increased physical activity. Exercise training notably resistance and aerobic exercise has been consistently shown to improve muscle mass, enhance myokine secretion, and reduce hepatic fat content independent of weight loss. Pharmacological agents such as insulin sensitizers (e.g., pioglitazone) and GLP-1 agonists may offer additional metabolic benefits. Addressing sarcopenia through tailored nutrition, protein supplementation, and structured exercise is integral to optimizing clinical outcomes. Multidisciplinary care, involving hepatologists, endocrinologists, and rehabilitation specialists, is recommended for comprehensive disease management.

Recent Advances / Emerging Therapies

Recent advances in understanding muscle-liver crosstalk have paved the way for novel therapeutic targets. Myostatin inhibitors, irisin analogs, and agents modulating muscle autophagy are under investigation for their potential to ameliorate both muscle atrophy and hepatic steatosis. SGLT2 inhibitors and dual agonists targeting GLP-1 and GIP receptors demonstrate promising effects on metabolic parameters, muscle mass, and liver health. Research into gene editing, mitochondrial modulators, and anti-inflammatory therapies continues to expand therapeutic horizons. Ongoing clinical trials will further clarify the role of these interventions in preventing and managing metabolic liver disease through modulation of muscle-liver interactions.

Guideline Recommendations

International guidelines, including those from EASL, AASLD, and APASL, now recognize the importance of muscle health in the context of metabolic liver disease. Routine assessment of muscle mass and function is advocated, particularly in high-risk populations. Physical activity specifically resistance training is recommended as a cornerstone of prevention and management. Lifestyle modification remains first-line therapy, with adjunctive pharmacotherapy considered for selected patients with advanced disease or comorbidities. Multidisciplinary, individualized care is strongly emphasized to address the multifactorial nature of muscle-liver crosstalk and optimize patient outcomes.

Conclusion

Muscle-liver crosstalk represents a crucial, yet previously underappreciated, axis in the prevention and management of metabolic liver disease. Integrating muscle-targeted interventions with traditional hepatic therapies offers a promising avenue for reducing disease burden and improving clinical outcomes. Ongoing research into the molecular mechanisms and therapeutic modulation of this crosstalk will further inform evidence-based practice. Clinicians are encouraged to adopt a comprehensive, multidisciplinary approach that addresses both hepatic and muscular health to effectively prevent and manage metabolic liver disease in at-risk populations.